Structure-based development of small molecule PFKFB3 inhibitors: A framework for potential cancer therapeutic agents targeting the Warburg effect

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Seo, Minsuh ^a   Kim, Jeong Do ^a   Neau, David ^b   Sehgal, Inder ^c   Lee, Yong Hwan ^a  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5,6,7,8 TETRAHYDROXY 2 (4 HYDROXYPHENYL)CHROMEN 4 ONE; 6 PHOSPHOFRUCTO 2 KINASE FRUCTOSE 2,6 BISPHOSPHATASE INHIBITOR; 7,8 DIHYDROXY 3 (4 HYDROXYPHENYL)CHROMEN 4 ONE; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; ETHYL 7 HYDROXY 2 OXOCHROMENE 3 CARBOXYLIC ACID; FRUCTOSE 2,6 BISPHOSPHONATE; UNCLASSIFIED DRUG; YN 1; YZ 9; 6 PHOSPHOFRUCTO 2 KINASE; BENZOPYRAN DERIVATIVE; ENZYME INHIBITOR; FRUCTOSE 6 PHOSPHATE; FRUCTOSE PHOSPHATE; FRUCTOSE-6-PHOSPHATE; PFKFB3 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER THERAPY; CELL DEATH; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG INFORMATION; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; GLYCOLYSIS; HUMAN; HUMAN CELL; IC 50; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DEVELOPMENT; DRUG EFFECT; HELA CELL; METABOLISM; METHODOLOGY; PROTEIN CONFORMATION;

ANTINEOPLASTIC AGENTS; BENZOPYRANS; CELL DEATH; CELL PROLIFERATION; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; FRUCTOSEPHOSPHATES; GLYCOLYSIS; HELA CELLS; HUMANS; MODELS, MOLECULAR; PHOSPHOFRUCTOKINASE-2; PROTEIN CONFORMATION;

EID: 80052988662     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024179     Document Type: Article

References (40)

1. Jones RG, Thompson CB, (2009) Tumor suppressors and cell metabolism: a recipe for cancer growth. Genes Dev 23: 537-548.
2. Warburg O, (1956) On the origin of cancer cells. Science 123: 309-314.
3. Vander Heiden MG, Cantley LC, Thompson CB, (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324: 1029-1033.
4. Garber K, (2006) Energy deregulation: licensing tumors to grow. Science 312: 1158-1159.
5. Hsu PP, Sabatini DM, (2008) Cancer cell metabolism: Warburg and beyond. Cell 134: 703-707.
6. Polyak K, Li Y, Zhu H, Lengauer C, Willson JK, et al. (1998) Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet 20: 291-293.
7. Gottlieb E, Tomlinson IP, (2005) Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 5: 857-866.
8. Pouyssegur J, Dayan F, Mazure NM, (2006) Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441: 437-443.
9. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB, (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7: 11-20.
10. Pelicano H, Martin DS, Xu RH, Huang P, (2006) Glycolysis inhibition for anticancer treatment. Oncogene 25: 4633-4646.
11. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, et al. (2005) Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res 65: 613-621.
12. Tennant DA, Duran RV, Gottlieb E, (2010) Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10: 267-277.
13. Pilkis SJ, Claus TH, Kurland IJ, Lange AJ, (1995) 6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase: a metabolic signaling enzyme. Annu Rev Biochem 64: 799-835.
14. El-Maghrabi MR, Noto F, Wu N, Manes N, (2001) 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: suiting structure to need, in a family of tissue-specific enzymes. Curr Opin Clin Nutr Metab Care 4: 411-418.
15. Van Schaftingen E, Jett MF, Hue L, Hers HG, (1981) Control of liver 6-phosphofructokinase by fructose 2,6-bisphosphate and other effectors. Proc Natl Acad Sci U S A 78: 3483-3486.
16. Nissler K, Petermann H, Wenz I, Brox D, (1995) Fructose 2,6-bisphosphate metabolism in Ehrlich ascites tumour cells. J Cancer Res Clin Oncol 121: 739-745.
17. Hue L, Rousseau GG, (1993) Fructose 2,6-bisphosphate and the control of glycolysis by growth factors, tumor promoters and oncogenes. Adv Enzyme Regul 33: 97-110.
18. Telang S, Yalcin A, Clem AL, Bucala R, Lane AN, et al. (2006) Ras transformation requires metabolic control by 6-phosphofructo-2-kinase. Oncogene 25: 7225-7234.
19. Rider MH, Bertrand L, Vertommen D, Michels PA, Rousseau GG, et al. (2004) 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase: head-to-head with a bifunctional enzyme that controls glycolysis. Biochem J 381: 561-579.
20. Minchenko O, Opentanova I, Caro J, (2003) Hypoxic regulation of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase gene family (PFKFB-1-4) expression in vivo. FEBS Lett 554: 264-270.
21. Atsumi T, Chesney J, Metz C, Leng L, Donnelly S, et al. (2002) High expression of inducible 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (iPFK-2; PFKFB3) in human cancers. Cancer Res 62: 5881-5887.
22. Calvo MN, Bartrons R, Castano E, Perales JC, Navarro-Sabate A, et al. (2006) PFKFB3 gene silencing decreases glycolysis, induces cell-cycle delay and inhibits anchorage-independent growth in HeLa cells. FEBS Lett 580: 3308-3314.
23. Minchenko A, Leshchinsky I, Opentanova I, Sang N, Srinivas V, et al. (2002) Hypoxia-inducible factor-1-mediated expression of the 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3) gene. Its possible role in the Warburg effect. J Biol Chem 277: 6183-6187.
24. Clem B, Telang S, Clem A, Yalcin A, Meier J, et al. (2008) Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth. Mol Cancer Ther 7: 110-120.
25. Kim SG, Manes NP, El-Maghrabi MR, Lee YH, (2006) Crystal structure of the hypoxia-inducible form of 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (PFKFB3): a possible new target for cancer therapy. J Biol Chem 281: 2939-2944.
26. Gohlke H, Hendlich M, Klebe G, (2000) Knowledge-based scoring function to predict protein-ligand interactions. J Mol Biol 295: 337-356.
27. McConkey DJ, (1998) Biochemical determinants of apoptosis and necrosis. Toxicol Lett 99: 157-168.
28. Richter C, Schweizer M, Cossarizza A, Franceschi C, (1996) Control of apoptosis by the cellular ATP level. FEBS Lett 378: 107-110.
29. Kim SG, Cavalier M, El-Maghrabi MR, Lee YH, (2007) A direct substrate-substrate interaction found in the kinase domain of the bifunctional enzyme, 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase. J Mol Biol 370: 14-26.
30. Perez JJ, (2005) Managing molecular diversity. Chem Soc Rev 34: 143-152.
31. Beene DL, Brandt GS, Zhong W, Zacharias NM, Lester HA, et al. (2002) Cation-pi interactions in ligand recognition by serotonergic (5-HT3A) and nicotinic acetylcholine receptors: the anomalous binding properties of nicotine. Biochemistry 41: 10262-10269.
32. Kuntz ID, (1992) Structure-based strategies for drug design and discovery. Science 257: 1078-1082.
33. Blundell TL, Jhoti H, Abell C, (2002) High-throughput crystallography for lead discovery in drug design. Nat Rev Drug Discov 1: 45-54.
34. Davies SP, Reddy H, Caivano M, Cohen P, (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351: 95-105.
35. Hanks SK, Quinn AM, Hunter T, (1988) The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 241: 42-52.
36. Van Schaftingen E, Lederer B, Bartrons R, Hers HG, (1982) A kinetic study of pyrophosphate: fructose-6-phosphate phosphotransferase from potato tubers. Application to a microassay of fructose 2,6-bisphosphate. Eur J Biochem 129: 191-195.
37. Cleland WW, (1979) Statistical analysis of enzyme kinetic data. Methods Enzymol 63: 103-138.
38. van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP, (1998) Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31: 1-9.
39. Kabsch W, (2010) Xds. Acta Crystallogr D Biol Crystallogr 66: 125-132.
40. Collaborative Computational Project (1994) The CCP4 suite: programs for protein crystallography. Acta Crystallogr D Biol Crystallogr 50: 760-763.